Skip to main content

Table 1 Health state probabilities used in the model, based on the TRIPLE study

From: Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan

Health state outcome by phase

PALO regimen N = 414 (%)

GRA regimen N = 413 (%)

Acute Phase

(day 1)

Delayed Phase (days 2–5)

Complete protection

Complete protection

58.7

50.4

Complete response at best

1.8

2.9

Incomplete response

29.6

36.9

Complete response at best

Complete protection

1.1

1.0

Complete response at best

0.0

0.1

Incomplete response

0.6

0.7

Incomplete response

Complete protection

5.3

4.6

Complete response at best

0.2

0.3

Incomplete response

2.7

3.4